Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Krka (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan Medoxomil, the active ingredient in Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Krka, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension, often in combination with other antihypertensive agents, and is suitable for adult patients. GNH USA supplies Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide is indicated for hypertension management, targeting the renin‑angiotensin system and calcium‑channel pathways.

- Hypertension: provides combined blood pressure reduction through three complementary mechanisms. - High‑risk cardiovascular patients: helps achieve target blood pressure when monotherapy is insufficient. - Edema associated with hypertension therapy: mitigates fluid retention via the thiazide diuretic component. - Stroke prevention (adjunct): contributes to lower stroke risk by maintaining optimal blood pressure levels. - Chronic kidney disease with hypertension: assists in slowing renal function decline by controlling systemic pressure.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness or light‑headedness - Headache - Peripheral edema - Flushing - Fatigue - Cough

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Electrolyte disturbances (e.g., hyponatremia, hyperkalemia) - Angio‑edema - Liver function abnormalities - Pancreatitis

When prescribing this combination, clinicians should consider several safety aspects.

- Renal function monitoring: assess creatinine and electrolytes before and during therapy. - Hepatic impairment: use cautiously and adjust dose if needed. - Pregnancy: contraindicated in the second and third trimesters due to fetal toxicity. - Hyperkalemia risk: monitor serum potassium, especially when combined with potassium‑sparing agents. - Orthostatic hypotension: advise patients to rise slowly from sitting or lying positions. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan Medoxomil/Amlodipine/Hydrochlorothiazide may interact with several drug classes.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): increased risk of renal dysfunction and hyperkalemia. - Potassium‑rich supplements or potassium‑sparing diuretics: may cause dangerous hyperkalemia. - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): elevate amlodipine levels, raising hypotension risk.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function. - Lithium: concurrent use can increase lithium concentrations, risking toxicity. - Antidiabetic agents: may enhance glucose‑lowering effect, requiring dose adjustment.